Bird flu hits world's largest poultry exporter Brazil
The outbreak in southern Brazil was identified at a farm supplying Vibra Foods, a Brazilian operation backed by Tyson Foods, according to two people familiar with the matter.
Vibra and Tyson did not immediately respond to questions.
Vibra has 15 processing plants in Brazil and exports to more than 60 countries, according to its website.
Brazil exported $US10 billion ($A16 billion) of chicken meat in 2024, accounting for about 35 per cent of global trade.
Much of that came from meat processors BRF and JBS, which ship to 150 countries.
China, Japan, Saudi Arabia and the United Arab Emirates are among the main destinations for Brazil's chicken exports.
Brazil's Agriculture Minister Carlos Favaro said on Friday China had banned poultry imports from the country for 60 days.
Under agreements with Japan, the UAE and Saudi Arabia, he said a trade ban would only restrict shipments from the affected state and, eventually, just the municipality in question.
The outbreak occurred in the city of Montenegro in Brazil's southernmost state of Rio Grande do Sul, the farm ministry said.
The state accounts for 15 per cent of Brazilian poultry production and exports, pork and poultry group ABPA said in July 2024.
BRF has five processing plants operating in the state.
JBS has also invested in local chicken processing plants under its Seara brand.
State officials said the outbreak of H5N1 bird flu is already responsible for the death of 17,000 farm chickens, either directly from the disease or due to cautionary culling.
Veterinary officials are isolating the area of the outbreak in Montenegro and hunting for more cases in an initial 10km radius, the state agricultural secretariat said.
Favaro, the farm minister, said Brazil was working to contain the outbreak and negotiate a loosening of trade restrictions faster than the two months agreed in protocols.
"If we manage to eliminate the outbreak, we think it's possible to re-establish a normal trade flow before the 60 days are up, including with China," Favaro said in an interview aired on CNN Brasil.
Chicken products shipped by Thursday will not be affected by trade restrictions, he added.
The ministry said in a statement that it was officially notifying the World Organisation for Animal Health.
Bird flu has swept through the US poultry industry since 2022, killing about 170 million chickens, turkeys and other birds, severely affecting production of meat and eggs.
Bird flu has also infected nearly 70 people in the US, with one death, since 2024.
Most of those infections have been among farm workers exposed to infected poultry or cows.
The further spread of the disease raises the risk that bird flu could become more transmissible to humans.
By contrast, Argentina was able to isolate a February 2023 outbreak and start resuming exports slowly the next month.
"All necessary measures to control the situation were quickly adopted, and the situation is under control and being monitored by government agencies," Brazil's poultry industry group ABPA said in a statement.
JBS referred questions about the outbreak to ABPA.
BRF CEO Miguel Gularte told analysts on an earnings call that he was confident Brazilian health protocols were robust and the situation would be quickly overcome.
Brazil, which exported more than five million metric tonnes of chicken products last year, first confirmed outbreaks of the highly pathogenic avian flu among wild birds in May 2023 in at least seven states.
The disease is not transmitted through the consumption of poultry meat or eggs, the Agriculture Ministry said.
"The Brazilian and world population can rest assured about the safety of inspected products, and there are no restrictions on their consumption," the ministry said.
Brazil, the world's largest chicken exporter, has confirmed its first outbreak of bird flu on a poultry farm, triggering a country-wide trade ban from China and state-wide restrictions for other major consumers.
The outbreak in southern Brazil was identified at a farm supplying Vibra Foods, a Brazilian operation backed by Tyson Foods, according to two people familiar with the matter.
Vibra and Tyson did not immediately respond to questions.
Vibra has 15 processing plants in Brazil and exports to more than 60 countries, according to its website.
Brazil exported $US10 billion ($A16 billion) of chicken meat in 2024, accounting for about 35 per cent of global trade.
Much of that came from meat processors BRF and JBS, which ship to 150 countries.
China, Japan, Saudi Arabia and the United Arab Emirates are among the main destinations for Brazil's chicken exports.
Brazil's Agriculture Minister Carlos Favaro said on Friday China had banned poultry imports from the country for 60 days.
Under agreements with Japan, the UAE and Saudi Arabia, he said a trade ban would only restrict shipments from the affected state and, eventually, just the municipality in question.
The outbreak occurred in the city of Montenegro in Brazil's southernmost state of Rio Grande do Sul, the farm ministry said.
The state accounts for 15 per cent of Brazilian poultry production and exports, pork and poultry group ABPA said in July 2024.
BRF has five processing plants operating in the state.
JBS has also invested in local chicken processing plants under its Seara brand.
State officials said the outbreak of H5N1 bird flu is already responsible for the death of 17,000 farm chickens, either directly from the disease or due to cautionary culling.
Veterinary officials are isolating the area of the outbreak in Montenegro and hunting for more cases in an initial 10km radius, the state agricultural secretariat said.
Favaro, the farm minister, said Brazil was working to contain the outbreak and negotiate a loosening of trade restrictions faster than the two months agreed in protocols.
"If we manage to eliminate the outbreak, we think it's possible to re-establish a normal trade flow before the 60 days are up, including with China," Favaro said in an interview aired on CNN Brasil.
Chicken products shipped by Thursday will not be affected by trade restrictions, he added.
The ministry said in a statement that it was officially notifying the World Organisation for Animal Health.
Bird flu has swept through the US poultry industry since 2022, killing about 170 million chickens, turkeys and other birds, severely affecting production of meat and eggs.
Bird flu has also infected nearly 70 people in the US, with one death, since 2024.
Most of those infections have been among farm workers exposed to infected poultry or cows.
The further spread of the disease raises the risk that bird flu could become more transmissible to humans.
By contrast, Argentina was able to isolate a February 2023 outbreak and start resuming exports slowly the next month.
"All necessary measures to control the situation were quickly adopted, and the situation is under control and being monitored by government agencies," Brazil's poultry industry group ABPA said in a statement.
JBS referred questions about the outbreak to ABPA.
BRF CEO Miguel Gularte told analysts on an earnings call that he was confident Brazilian health protocols were robust and the situation would be quickly overcome.
Brazil, which exported more than five million metric tonnes of chicken products last year, first confirmed outbreaks of the highly pathogenic avian flu among wild birds in May 2023 in at least seven states.
The disease is not transmitted through the consumption of poultry meat or eggs, the Agriculture Ministry said.
"The Brazilian and world population can rest assured about the safety of inspected products, and there are no restrictions on their consumption," the ministry said.
Brazil, the world's largest chicken exporter, has confirmed its first outbreak of bird flu on a poultry farm, triggering a country-wide trade ban from China and state-wide restrictions for other major consumers.
The outbreak in southern Brazil was identified at a farm supplying Vibra Foods, a Brazilian operation backed by Tyson Foods, according to two people familiar with the matter.
Vibra and Tyson did not immediately respond to questions.
Vibra has 15 processing plants in Brazil and exports to more than 60 countries, according to its website.
Brazil exported $US10 billion ($A16 billion) of chicken meat in 2024, accounting for about 35 per cent of global trade.
Much of that came from meat processors BRF and JBS, which ship to 150 countries.
China, Japan, Saudi Arabia and the United Arab Emirates are among the main destinations for Brazil's chicken exports.
Brazil's Agriculture Minister Carlos Favaro said on Friday China had banned poultry imports from the country for 60 days.
Under agreements with Japan, the UAE and Saudi Arabia, he said a trade ban would only restrict shipments from the affected state and, eventually, just the municipality in question.
The outbreak occurred in the city of Montenegro in Brazil's southernmost state of Rio Grande do Sul, the farm ministry said.
The state accounts for 15 per cent of Brazilian poultry production and exports, pork and poultry group ABPA said in July 2024.
BRF has five processing plants operating in the state.
JBS has also invested in local chicken processing plants under its Seara brand.
State officials said the outbreak of H5N1 bird flu is already responsible for the death of 17,000 farm chickens, either directly from the disease or due to cautionary culling.
Veterinary officials are isolating the area of the outbreak in Montenegro and hunting for more cases in an initial 10km radius, the state agricultural secretariat said.
Favaro, the farm minister, said Brazil was working to contain the outbreak and negotiate a loosening of trade restrictions faster than the two months agreed in protocols.
"If we manage to eliminate the outbreak, we think it's possible to re-establish a normal trade flow before the 60 days are up, including with China," Favaro said in an interview aired on CNN Brasil.
Chicken products shipped by Thursday will not be affected by trade restrictions, he added.
The ministry said in a statement that it was officially notifying the World Organisation for Animal Health.
Bird flu has swept through the US poultry industry since 2022, killing about 170 million chickens, turkeys and other birds, severely affecting production of meat and eggs.
Bird flu has also infected nearly 70 people in the US, with one death, since 2024.
Most of those infections have been among farm workers exposed to infected poultry or cows.
The further spread of the disease raises the risk that bird flu could become more transmissible to humans.
By contrast, Argentina was able to isolate a February 2023 outbreak and start resuming exports slowly the next month.
"All necessary measures to control the situation were quickly adopted, and the situation is under control and being monitored by government agencies," Brazil's poultry industry group ABPA said in a statement.
JBS referred questions about the outbreak to ABPA.
BRF CEO Miguel Gularte told analysts on an earnings call that he was confident Brazilian health protocols were robust and the situation would be quickly overcome.
Brazil, which exported more than five million metric tonnes of chicken products last year, first confirmed outbreaks of the highly pathogenic avian flu among wild birds in May 2023 in at least seven states.
The disease is not transmitted through the consumption of poultry meat or eggs, the Agriculture Ministry said.
"The Brazilian and world population can rest assured about the safety of inspected products, and there are no restrictions on their consumption," the ministry said.
Brazil, the world's largest chicken exporter, has confirmed its first outbreak of bird flu on a poultry farm, triggering a country-wide trade ban from China and state-wide restrictions for other major consumers.
The outbreak in southern Brazil was identified at a farm supplying Vibra Foods, a Brazilian operation backed by Tyson Foods, according to two people familiar with the matter.
Vibra and Tyson did not immediately respond to questions.
Vibra has 15 processing plants in Brazil and exports to more than 60 countries, according to its website.
Brazil exported $US10 billion ($A16 billion) of chicken meat in 2024, accounting for about 35 per cent of global trade.
Much of that came from meat processors BRF and JBS, which ship to 150 countries.
China, Japan, Saudi Arabia and the United Arab Emirates are among the main destinations for Brazil's chicken exports.
Brazil's Agriculture Minister Carlos Favaro said on Friday China had banned poultry imports from the country for 60 days.
Under agreements with Japan, the UAE and Saudi Arabia, he said a trade ban would only restrict shipments from the affected state and, eventually, just the municipality in question.
The outbreak occurred in the city of Montenegro in Brazil's southernmost state of Rio Grande do Sul, the farm ministry said.
The state accounts for 15 per cent of Brazilian poultry production and exports, pork and poultry group ABPA said in July 2024.
BRF has five processing plants operating in the state.
JBS has also invested in local chicken processing plants under its Seara brand.
State officials said the outbreak of H5N1 bird flu is already responsible for the death of 17,000 farm chickens, either directly from the disease or due to cautionary culling.
Veterinary officials are isolating the area of the outbreak in Montenegro and hunting for more cases in an initial 10km radius, the state agricultural secretariat said.
Favaro, the farm minister, said Brazil was working to contain the outbreak and negotiate a loosening of trade restrictions faster than the two months agreed in protocols.
"If we manage to eliminate the outbreak, we think it's possible to re-establish a normal trade flow before the 60 days are up, including with China," Favaro said in an interview aired on CNN Brasil.
Chicken products shipped by Thursday will not be affected by trade restrictions, he added.
The ministry said in a statement that it was officially notifying the World Organisation for Animal Health.
Bird flu has swept through the US poultry industry since 2022, killing about 170 million chickens, turkeys and other birds, severely affecting production of meat and eggs.
Bird flu has also infected nearly 70 people in the US, with one death, since 2024.
Most of those infections have been among farm workers exposed to infected poultry or cows.
The further spread of the disease raises the risk that bird flu could become more transmissible to humans.
By contrast, Argentina was able to isolate a February 2023 outbreak and start resuming exports slowly the next month.
"All necessary measures to control the situation were quickly adopted, and the situation is under control and being monitored by government agencies," Brazil's poultry industry group ABPA said in a statement.
JBS referred questions about the outbreak to ABPA.
BRF CEO Miguel Gularte told analysts on an earnings call that he was confident Brazilian health protocols were robust and the situation would be quickly overcome.
Brazil, which exported more than five million metric tonnes of chicken products last year, first confirmed outbreaks of the highly pathogenic avian flu among wild birds in May 2023 in at least seven states.
The disease is not transmitted through the consumption of poultry meat or eggs, the Agriculture Ministry said.
"The Brazilian and world population can rest assured about the safety of inspected products, and there are no restrictions on their consumption," the ministry said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
2 days ago
- Sydney Morning Herald
‘Absolutely dire': How it all went wrong for Ozempic's maker after creating a wonder drug
Ozempic, which came onto the market in late 2017, led to substantial weight loss and quickly attracted cultural cachet, not least because of its use among celebrities. TikTok videos documenting people's experience with Ozempic attracted millions of views. Analysts predicted that it could tap into an enormous market, since 1 billion people in the world are considered obese. In the first half of the year, Novo Nordisk made $US10 billion in sales from Ozempic, of which 70 per cent was in the United States. For a company that had been focused on the steady business of selling insulin, the popularity of Ozempic took its executives by surprise. In 2021, they started selling Wegovy, semaglutide marketed specifically for weight loss, but demand was so high that the company struggled to meet it. That shortage 'opened a whole can of worms', said Rajesh Kumar, an analyst at HSBC. An FDA decision opens the door for copycats In 2022, semaglutide landed on the Food and Drug Administration's shortage list, which spurred production of cheaper copycat versions of Novo Nordisk's drugs. To ensure the supply of medicines facing shortages, US federal law allows companies to produce versions of patented drugs via a process of mixing ingredients called compounding. Loading The FDA said this year that the shortage was over and ordered producers and sellers of the copycat weight-loss drugs to wind down. But Novo Nordisk said that never happened. Compounders have continued to offer what they call 'personalised' versions of the drugs, a legally murky practice that they claim is allowed by the law. Novo Nordisk said last week that more than 1 million people were still using compounded GLP-1s, eating into the company's market share and forcing it to slash sales and profit forecasts. Its shares promptly dropped more than 20 per cent, erasing more than $US70 billion ($107 billion) in market value in a day, and some analysts lowered their recommendations on the company. One of them was Kumar, who had been advising investors to buy Novo Nordisk's shares for at least two years before downgrading last week to 'hold'. Compounding was part of the reason. 'Novo is issuing a lot of cease-and-desist orders, but it has been very difficult to stop them,' he said, adding he had never seen compounding at this scale before. On Wednesday, Novo Nordisk said it had filed 14 new lawsuits against compounders the day before. 'It's important that we get compounding off the market because right now it has equal size of our business,' said Lars Fruergaard Jorgensen, the departing CEO. Compounders, in particular, have targeted Wegovy because it was the most well-known brand, Kumar said. That has helped Eli Lilly to get an edge. Eli Lilly catches up, and then some Novo Nordisk had a huge head start. After Ozempic went on sale, it was another 4½ years before a serious competitor emerged: Eli Lilly's Mounjaro, the brand name for tirzepatide, a drug used to treat diabetes. Mounjaro proved to be more effective, leading to greater weight loss in clinical trials. Many patients said they preferred it. At the start of this year, Eli Lilly's Zepbound, which is tirzepatide marketed for weight loss, passed Wegovy in new prescriptions in the United States, according to IQVIA, an analytics company. Unlike Novo Nordisk, Eli Lilly also found ways to get its product to consumers more cheaply, and compete with telehealth companies offering compounded copycat versions, by selling its drug in vials with syringes instead of the more expensive pens with prefilled doses. Novo Nordisk was further hampered by its slowness in introducing a direct-to-consumer sales platform. NovoCare Pharmacy launched in March, 14 months after LillyDirect. 'Lilly was doing all these things, and Novo wasn't,' said Emily Field, an analyst at Barclays, who recently downgraded the stock. 'It felt like a lot of this was one big own goal,' she said. Novo's pipeline struggles to impress More than anything, a company's market value is determined by investors' expectations for earnings in the future. For a pharmaceutical company, that means the drugs in its pipeline. This has helped Eli Lilly's stock outperform Novo Nordisk's this year. Loading Investors and analysts are particularly interested in the prospects of weight-loss pills, which could reach more patients than injections. Eli Lilly's daily pill, orforglipron, has been showing promising results in late-stage clinical trials, with similar weight loss to Novo Nordisk's injections and fewer restrictions on its use. Novo Nordisk's oral tablet leads to less weight loss than its injections, but the company has other pills in development. On Thursday, Eli Lilly said its orforglipron tablets led to 12 per cent weight loss, slightly less than analysts expected, which dented Eli Lilly's shares and gave Novo Nordisk's a boost. But Eli Lilly also raised its overall earnings forecast for the year, on greater demand for Zepbound. In developing its pipeline, Eli Lilly is 'deploying capital and running faster than Novo in a market that isn't going to be patient in any way,' said Seamus Fernandez, an analyst at Guggenheim Partners. Can a new leader make a difference? The Novo Nordisk Foundation, which controls Novo Nordisk through its holding company, has also grown impatient. At the foundation's urging, Jorgensen, who had been CEO of the company since Ozempic came onto the market, stepped down. Maziar Mike Doustdar took over the top role on Thursday, the first non-Dane to run the company. Doustdar, an Iranian-born Austrian citizen who grew up in the United States, joined the company in 1992, for what he thought would be a summer job making photocopies. 'He has a bias for speed, for pace and for action,' Helge Lund, the chair of the board of directors, said when announcing Doustdar's appointment. Loading Concerns are mounting that analysts may have overestimated the potential size of the weight-loss market, or at least how easily more people will gain access to these drugs. At the same time, US President Donald Trump is pressuring companies to lower drug prices and threatening tariffs on medicines produced abroad, casting a cloud over pharma firms' business models. 'I still believe there's a big market,' said Powell of Polar Capital, which invests in Novo Nordisk and Eli Lilly. But broad concerns about the market are hitting Novo Nordisk hardest, he added.
The Age
2 days ago
- The Age
‘Absolutely dire': How it all went wrong for Ozempic's maker after creating a wonder drug
Ozempic, which came onto the market in late 2017, led to substantial weight loss and quickly attracted cultural cachet, not least because of its use among celebrities. TikTok videos documenting people's experience with Ozempic attracted millions of views. Analysts predicted that it could tap into an enormous market, since 1 billion people in the world are considered obese. In the first half of the year, Novo Nordisk made $US10 billion in sales from Ozempic, of which 70 per cent was in the United States. For a company that had been focused on the steady business of selling insulin, the popularity of Ozempic took its executives by surprise. In 2021, they started selling Wegovy, semaglutide marketed specifically for weight loss, but demand was so high that the company struggled to meet it. That shortage 'opened a whole can of worms', said Rajesh Kumar, an analyst at HSBC. An FDA decision opens the door for copycats In 2022, semaglutide landed on the Food and Drug Administration's shortage list, which spurred production of cheaper copycat versions of Novo Nordisk's drugs. To ensure the supply of medicines facing shortages, US federal law allows companies to produce versions of patented drugs via a process of mixing ingredients called compounding. Loading The FDA said this year that the shortage was over and ordered producers and sellers of the copycat weight-loss drugs to wind down. But Novo Nordisk said that never happened. Compounders have continued to offer what they call 'personalised' versions of the drugs, a legally murky practice that they claim is allowed by the law. Novo Nordisk said last week that more than 1 million people were still using compounded GLP-1s, eating into the company's market share and forcing it to slash sales and profit forecasts. Its shares promptly dropped more than 20 per cent, erasing more than $US70 billion ($107 billion) in market value in a day, and some analysts lowered their recommendations on the company. One of them was Kumar, who had been advising investors to buy Novo Nordisk's shares for at least two years before downgrading last week to 'hold'. Compounding was part of the reason. 'Novo is issuing a lot of cease-and-desist orders, but it has been very difficult to stop them,' he said, adding he had never seen compounding at this scale before. On Wednesday, Novo Nordisk said it had filed 14 new lawsuits against compounders the day before. 'It's important that we get compounding off the market because right now it has equal size of our business,' said Lars Fruergaard Jorgensen, the departing CEO. Compounders, in particular, have targeted Wegovy because it was the most well-known brand, Kumar said. That has helped Eli Lilly to get an edge. Eli Lilly catches up, and then some Novo Nordisk had a huge head start. After Ozempic went on sale, it was another 4½ years before a serious competitor emerged: Eli Lilly's Mounjaro, the brand name for tirzepatide, a drug used to treat diabetes. Mounjaro proved to be more effective, leading to greater weight loss in clinical trials. Many patients said they preferred it. At the start of this year, Eli Lilly's Zepbound, which is tirzepatide marketed for weight loss, passed Wegovy in new prescriptions in the United States, according to IQVIA, an analytics company. Unlike Novo Nordisk, Eli Lilly also found ways to get its product to consumers more cheaply, and compete with telehealth companies offering compounded copycat versions, by selling its drug in vials with syringes instead of the more expensive pens with prefilled doses. Novo Nordisk was further hampered by its slowness in introducing a direct-to-consumer sales platform. NovoCare Pharmacy launched in March, 14 months after LillyDirect. 'Lilly was doing all these things, and Novo wasn't,' said Emily Field, an analyst at Barclays, who recently downgraded the stock. 'It felt like a lot of this was one big own goal,' she said. Novo's pipeline struggles to impress More than anything, a company's market value is determined by investors' expectations for earnings in the future. For a pharmaceutical company, that means the drugs in its pipeline. This has helped Eli Lilly's stock outperform Novo Nordisk's this year. Loading Investors and analysts are particularly interested in the prospects of weight-loss pills, which could reach more patients than injections. Eli Lilly's daily pill, orforglipron, has been showing promising results in late-stage clinical trials, with similar weight loss to Novo Nordisk's injections and fewer restrictions on its use. Novo Nordisk's oral tablet leads to less weight loss than its injections, but the company has other pills in development. On Thursday, Eli Lilly said its orforglipron tablets led to 12 per cent weight loss, slightly less than analysts expected, which dented Eli Lilly's shares and gave Novo Nordisk's a boost. But Eli Lilly also raised its overall earnings forecast for the year, on greater demand for Zepbound. In developing its pipeline, Eli Lilly is 'deploying capital and running faster than Novo in a market that isn't going to be patient in any way,' said Seamus Fernandez, an analyst at Guggenheim Partners. Can a new leader make a difference? The Novo Nordisk Foundation, which controls Novo Nordisk through its holding company, has also grown impatient. At the foundation's urging, Jorgensen, who had been CEO of the company since Ozempic came onto the market, stepped down. Maziar Mike Doustdar took over the top role on Thursday, the first non-Dane to run the company. Doustdar, an Iranian-born Austrian citizen who grew up in the United States, joined the company in 1992, for what he thought would be a summer job making photocopies. 'He has a bias for speed, for pace and for action,' Helge Lund, the chair of the board of directors, said when announcing Doustdar's appointment. Loading Concerns are mounting that analysts may have overestimated the potential size of the weight-loss market, or at least how easily more people will gain access to these drugs. At the same time, US President Donald Trump is pressuring companies to lower drug prices and threatening tariffs on medicines produced abroad, casting a cloud over pharma firms' business models. 'I still believe there's a big market,' said Powell of Polar Capital, which invests in Novo Nordisk and Eli Lilly. But broad concerns about the market are hitting Novo Nordisk hardest, he added.
Perth Now
2 days ago
- Perth Now
Plan to save A-League club from folding
Western United's current investors are hoping to save the club from A-League extinction rather than rely on proposed new owners KAM Melbourne. Stripped of its A-League licence last Friday by Football Australia, United has until Saturday to lodge an appeal against the decision, which was made due to the financially embattled Victorian club's failure to meet the criteria required for a licence. United and its parent company Western Melbourne Group had hoped its financial woes – including a six-figure sum owed to the club's former striker Aleksandar Prijovic and a multimillion-dollar tax debt reportedly owed by United chairman Jason Sourasis – were solved by a proposed $100 million investment from KAM Melbourne that was announced in May. However, the Australian Professional Leagues, which runs the A-League, is yet to receive the completed ownership proposal from KAM Melbourne, a subsidiary of American company KAS Sports. With ongoing uncertainty about KAM Melbourne's ability to submit a viable proposal, it's understood investors that make up WMG – which is headed by Sourasis – have been advised and encouraged to pay the club's debts to ensure United's future. Paying Prijovic would lead to FIFA lifting the ban it imposed on United from registering new signings. That, as well as payment of the tax bill, would go a long towards United's appeal against being stripped off its licence being successful. United's squad continues to train at the club's Tarneit base under coach, Socceroos great John Aloisi. Under the guidance of Aloisi, United won the 2022 A-League championship, with Switzerland-born Serbian international Prijovic having played a leading role in the club's 2-0n grand final win over Melbourne City at AAMI Park. Western United Captain Josh Risdon, Head Coach John Aloisi and Star Brazilian Striker Daniel Penha. Linda Higginson Credit: News Corp Australia Meanwhile, Socceroos defender Jason Davidson has rejoined Melbourne Victory on a two-year deal. Davidson, 34, spent the 2021-22 season with the Victory before spend the past three years in Europe with stints at Eupen (Belgium) and Panserraikos (Greece). 'Returning to Victory after three years in Europe is incredibly exciting,' Davidson said. 'My time overseas has only made me more hungry for success. I intend to bring my best to the team, alongside the rest of the playing group, and help drive success this season.' Victory coach Arthur Diles said: 'Jason has proven his ability to be a game changer in both the A-League and on the international stage.'
